Clinical Trials Logo

Solid Tumors clinical trials

View clinical trials related to Solid Tumors.

Filter by:

NCT ID: NCT04029688 Active, not recruiting - Solid Tumors Clinical Trials

A Study Evaluating the Safety, Tolerability, Pharmacokinetics and Preliminary Activity of Idasanutlin in Combination With Either Chemotherapy or Venetoclax in Treatment of Pediatric and Young Adult Participants With Relapsed/Refractory Acute Leukemias or Solid Tumors

Start date: January 27, 2020
Phase: Phase 1/Phase 2
Study type: Interventional

This is a Phase I/II, multicenter, open-label, multi-arm study designed to evaluate the safety, tolerability, pharmacokinetics, and preliminary efficacy of idasanutlin, administered as a single agent or in combination with chemotherapy or venetoclax, in pediatric and young adult participants with acute leukemias or solid tumors. This study is divided into three parts: Part 1 will begin with dose escalation of idasanutlin as a single agent in pediatric participants with relapsed or refractory solid tumors to identify the maximum tolerated dose (MTD)/maximum administered dose (MAD) and to characterize dose-limiting toxicities (DLTs). Following MTD/MAD identification, three separate safety run-in cohorts in neuroblastoma, acute myeloid leukemia (AML), and acute lymphoblastic leukemia (ALL) will be conducted to identify the recommended Phase 2 dose (RP2D) of idasanutlin in each combination, with chemotherapy or venetoclax. Part 2 will evaluate the safety and early efficacy of idasanutlin in combination with chemotherapy or venetoclax in newly enrolled pediatric and young adult participants in neuroblastoma, AML,and ALL cohorts at idasanutlin RP2D. Part 3 will potentially be conducted as an additional expansion phase of the idasanutlin combination cohorts in neuroblastoma, AML, or ALL for further response and safety assessment.

NCT ID: NCT04009460 Terminated - Neoplasms Clinical Trials

A Study of ES101 (PD-L1x4-1BB Bispecific Antibody) in Patients With Advanced Solid Tumors

Start date: June 28, 2019
Phase: Phase 1
Study type: Interventional

The purpose of this study is to evaluate the safety, tolerance and Dose-Limiting Toxicity (DLT) of recombinant humanized PD-L1/4-1BB bispecific antibody (ES101) in patients with advanced solid tumors.

NCT ID: NCT03998345 Recruiting - Solid Tumors Clinical Trials

Phase 1, First in Human, Open-Label, Dose-Escalation Study of 609A in China

Start date: July 25, 2020
Phase: N/A
Study type: Interventional

Phase 1, First in Human, Open-Label, Dose-Escalation Study of 609A in the Patients with Locally advanced/Metastatic Solid Tumors in China.

NCT ID: NCT03965845 Completed - Solid Tumors Clinical Trials

A Study of Telaglenastat (CB-839) in Combination With Palbociclib in Patients With Solid Tumors

Start date: June 25, 2019
Phase: Phase 1/Phase 2
Study type: Interventional

This is a Phase 1b/2 study to determine the recommended phase 2 dose (RP2D), safety and tolerability, pharmacokinetics (PK) and clinical activity of the glutaminase inhibitor telaglenestat (CB-839) with the CDK4/6 Inhibitor, palbociclib in participants with advanced/metastatic solid tumors.

NCT ID: NCT03954067 Completed - Solid Tumors Clinical Trials

A Study of an Intratumoral Oncolytic Virus in Patients With Advanced Metastatic Solid Tumors

Start date: August 8, 2019
Phase: Phase 1
Study type: Interventional

The purpose of this study is to assess the safety and tolerability of ASP9801 and to determine the recommended phase 2 dose (RP2D). The study will also evaluate antitumor activity, objective response rate, pharmacokinetics and virus shedding of ASP9801 as a single agent, as well as in combination with pembrolizumab, an anti-programmed cell death protein 1 (PD-1) checkpoint inhibitor.

NCT ID: NCT03950297 Recruiting - Solid Tumors Clinical Trials

Phase 1, First in Human, Open-Label, Dose-Escalation Study of 609A

Start date: May 1, 2019
Phase: Phase 1
Study type: Interventional

Phase 1, First in Human, Open-Label, Dose-Escalation Study of 609A in the Patients with Locally advanced/Metastatic Solid Tumors

NCT ID: NCT03946800 Completed - Cancer Clinical Trials

A Study of MEDI1191 in Sequential and Concurrent Combination With Durvalumab in Subjects With Advanced Solid Tumors

Start date: May 8, 2019
Phase: Phase 1
Study type: Interventional

To evaluate MEDI1191 administered intratumorally in sequential and concurrent combination with intravenous durvalumab in patients with solid tumors.

NCT ID: NCT03934372 Recruiting - Lymphoma Clinical Trials

Safety and Efficacy of Ponatinib for Treatment of Pediatric Recurrent or Refractory Leukemias, Lymphomas or Solid Tumors

Start date: January 29, 2020
Phase: Phase 1/Phase 2
Study type: Interventional

The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics, and efficacy of ponatinib in children aged 1 to < 18 years with advanced leukemias, lymphomas, and solid tumors.

NCT ID: NCT03926143 Terminated - Solid Tumors Clinical Trials

A Clinical Study of Anetumab Ravtansine in Adults With Solid Tumors Who Have Been Treated in Previous Bayer-sponsored Anetumab Ravtansine Studies

Start date: June 3, 2019
Phase: Phase 2
Study type: Interventional

The purpose of this study is to enable patients with solid tumors, who received anetumab ravtansine in a Bayer-sponsored clinical trial, to continue treatment after their respective study has been closed. The patients will be observed to collect information on how safe and efficient the drug is.

NCT ID: NCT03917381 Active, not recruiting - Clinical trials for Non-small Cell Lung Cancer

GEN1046 Safety Trial in Patients With Malignant Solid Tumors

Start date: May 14, 2019
Phase: Phase 1/Phase 2
Study type: Interventional

The purpose of the trial is to evaluate the safety of acasunlimab (also known as GEN1046) as monotherapy and in combination therapies in patients with malignant solid tumors